Abstract
827P First real-life data on olaparib in 1st line (1stL) maintenance BRCA1/2 mutated epithelial ovarian cancer (EOC) in France: Descriptive analysis of 201 patients (pts) enrolled in the cohort temporary authorization for use (ATUc)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have